Tourangeau Greg 4
4 · Fulcrum Therapeutics, Inc. · Filed May 11, 2023
Insider Transaction Report
Form 4
Tourangeau Greg
Principal Accounting Officer
Transactions
- Sale
Common Stock
2023-05-10$3.31/sh−210$695→ 15,992 total
Footnotes (1)
- [F1]The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.